According to a recent LinkedIn post from Astraveus, the company plans to participate in the Cell & Gene Therapy Summit at ChinaBio in Shanghai on April 28–29, marking its first congress presence in China. The post notes that CEO and founder Jérémie Laurent will present an overview of Lakhesys™, its microfluidics-based all‑in‑one platform, focusing on how microfluidic bioprocessing could address bottlenecks in cell therapy manufacturing from discovery to commercialization.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also indicates that Business Development Specialist Paul Cochard-Marchewka, PhD, will present a poster titled “Small is Powerful: Demonstrating the Potential of a Novel Microfluidic Benchsize Cell Factory to Optimize & Scale CAR-T Manufacturing,” including new data. By highlighting engagement with China’s fast‑growing cell and gene therapy ecosystem and positioning Lakhesys™ within CAR-T manufacturing workflows, the activity may signal Astraveus’s intent to explore partnerships, validate its technology in a key growth market, and potentially expand its future commercial footprint in Asia.
The LinkedIn post further emphasizes that Astraveus aims both to present and to listen, suggesting a strategic focus on understanding evolving innovation, manufacturing practices, and partnership models in China’s CGT landscape. For investors, this outreach could be interpreted as an early-stage business development and market-intelligence effort that, if successful, might support longer-term revenue opportunities, collaborative R&D initiatives, or strategic alliances tied to cell therapy manufacturing solutions.